Sign up
Pharma Capital

Physiomics PLC: Personalised medicines will build on momentum from recent pharma deals

Jim MIllen, Physiomics Plc's chief executive, explains how the trend towards personalised medicines will aid the commercialisation of its virtual tumour software.

UK development agency Innovate has given the group two grants to help with research in the area.

That follows deals with two large pharmaceutical companies and a biotech this year for the cancer modelling software.

Physiomics had already announced a €500,000 contract with German group Merck Serono at the end of 2017.

 

View full PYC profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.